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ABSTRACT: Assessment of outcome in preclinical studies of vascular cognitive impairment (VCI) is 
heterogenous.  Through an ARUK Scottish Network supported questionnaire and workshop (mostly 
UK-based researchers), we aimed to determine underlying variability and what could be implemented 
to overcome identified challenges.  Twelve UK VCI research centres were identified and invited to 
complete a questionnaire and attend a one-day workshop.  Questionnaire responses demonstrated 
agreement that outcome assessments in VCI preclinical research vary by group and even those 
common across groups, may be performed differently.  From the workshop, 6 themes were discussed: 
issues with preclinical models, reasons for choosing functional assessments, issues in interpretation of 
functional assessments, describing and reporting functional outcome assessments, sharing resources 
and expertise, and standardization of outcomes.  Eight consensus points emerged demonstrating 
broadly that the chosen assessment should reflect the deficit being measured and therefore, that one 
assessment does not suit all models; guidance/standardisation on recording VCI outcome reporting is 
needed and that uniformity would be aided by a platform to share expertise, material, protocols and 
procedures thus reducing heterogeneity and so increasing potential for collaboration, comparison and 
replication.  As a result of the workshop, UK wide consensus statements were agreed and future 
priorities for preclinical research identified. 
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INTRODUCTION 
Dementia is a clinical and research priority condition 1, yet despite our best efforts we still have few 
proven treatments for the disease 2, 3.  In vascular-related dementias, the therapeutic options are 
especially limited 4.  Recent years have seen concerted efforts to try and progress the dementia 
research agenda and improve the dementia drug discovery pipeline 5.  As in many disease areas, with 
stroke being the most relevant example, a rate limiting step in translational dementia research has been 
inconsistent or inefficient study outcomes measurements 6.   
 
Reviews of the literature suggest that heterogeneity in outcome assessment is a particular issue across 
all dementia studies 7.  Our objectives were to describe how outcomes are assessed in pre-clinical 
vascular cognition studies and to explore expert opinions on the optimal approaches to testing.  We 
described the UK perspective, through a focussed review of the literature, convening a one-day 
workshop, complemented by questionnaire data from those centres with active pre-clinical vascular 
dementia research programs.  In this report, we provide context by describing the issues and potential 
solutions to outcome assessment in other disease areas, notably stroke.  The findings of a literature 
review and the questionnaire and opinions from the workshop are then analysed and summarised into 
a set of consensus statements and priority directions for future research. 
 
Vascular cognitive impairment research  
Vascular cognitive impairment (VCI) is a term that encompasses a spectrum of cognitive syndromes 8.  
The common feature is that the predominant underlying pathology is of vascular origin.  VCI includes 
all forms of vascular dementia, cerebral amyloid angiopathy and also milder cognitive phenotypes that 
do not meet the dementia criteria.  Vascular disease is generally said to be the second most common 
cause of dementia after Alzheimer’s disease (AD) 8.  However, there is increasing evidence that 
dementia in older age is driven by more than one process and a vascular component mixed with AD or 
other pathologies is common 9.  Thus within the VCI remit there is a spectrum of both cognitive 
syndromes and underlying pathological states.  The two do not necessarily map neatly on to each other.  
Regardless of how VCI is categorised, it represents a major and increasing cause of disability. 
 Despite the importance of VCI, compared to other dementias such as AD, vascular causes of cognitive 
decline are relatively under-researched.  The landscape is evolving and clinical, research and policy 
interest in VCI is increasing.  The use of multi-centre cohorts 10, ‘big data’ and novel approaches to trials 
11 are all welcome developments but there remains an important role for pre-clinical research 10, not 
least because at present we have no proven and internationally licensed treatment options for VCI.  
 
The traditional process of drug discovery and development has had only limited success in VCI and 
dementia in general.  Many potential therapeutic agents have shown promise in pre-clinical studies and 
early human phase II studies, however, these were shown to have no beneficial effect when tested in 
definitive phase III randomised controlled trials (RCTs) 12.  Recent neutral results across a portfolio of 
putative AD treatments provide further evidence of the difficulty in the bench to bedside translation 13.  
One conclusion, which parts of the pharmaceutical industry are considering, is that this whole approach 
is misconceived.  Before reaching such a conclusion, however, it should be asked whether there are 
key aspects that currently hamper translation that could be improved.  Choice and translatability of 
outcome measures is one possible area.  Certainly, for the research community, the message seems 
to be that the status quo is not working and that all aspects of the pipeline should be reconsidered.  
Choice of outcome assessment and the methods used to perform these assessments is an important 
aspect of study methodology and there may be potential to improve practice.  Moving forward, a bedside 
to bench approach that better models the clinical condition is likely to uncover mechanisms that can be 
targeted pharmacologically or remedially for improved translation. 
 
Learning from stroke research  
The themes described in our discussion of VCI research, namely: a substantial clinical problem with 
limited pharmacological treatments, multiple positive preclinical treatments and frequently disappointing 
phase III results; were all true of stroke research in the 1990s and early 2000s.  Reflecting on the 
developments in contemporary stroke research can offer some guidance for how we approach VCI 
research.  A series of high profile neutral results for neuro-protectant agents was a driver for the stroke 
research community to critically reflect on their approach to drug development 14.  Various working 
groups were convened, that incorporated stakeholders from all aspects of the translational pathway 
including industry and regulatory representatives.  Documents and guidance, such as the materials 
produced by the various Stroke Treatment Academic Industry Roundtable (STAIR) meetings and the 
Collaborative Approach to Meta Analysis and Review of Animal Data from Experimental Studies 
(CAMARADES) group, have helped increase efficiency and rigor in many aspects of the translational 
approach 15-17.  Many of the recommendations of STAIR and CAMARADES have been adopted by 
funders, journal editors and regulatory agencies.  It is difficult to quantify the success of these programs 
and we should be cautious in ascribing changes in stroke research success to these initiatives.  
However, it is encouraging to see the growth in positive trial results from new interventional, 
pharmaceutical and device-based interventions in stroke 18-20.   
 
A key consideration of STAIR was to improve methods and reporting of outcomes and trial end-points.  
It was recognised that stroke trialists were using a variety of different methods to quantify treatment 
effects with no consensus on optimal measures or approaches 21.  This heterogeneity in assessment is 
problematic as it complicates any attempt to compare results or pool data for meta-analyses.  
Heterogeneity in outcome assessment is particularly apparent when cognitive tests are used as 
outcomes in stroke studies 22, 23.  In fact, a recent review suggested that there were more assessments 
than there were trials.  In response, a set of core outcomes measures for stroke trials were suggested 
with preferred tests for describing stroke impairments and activity limitations 24.  The concept of core 
outcomes for stroke trials has been adopted by many specialist societies and by regulatory agencies 25, 
26.  The move towards a more standardised approach to outcome assessment is not unique to stroke.  
In many other disease areas, heterogeneity and inconsistency in outcome assessment is noted.  The 
Core Outcome Measures in Effectiveness Trials (COMET) initiative aims to create and apply core 
outcome sets 27.  COMET guidance has created core outcome sets for many disease areas, recognising 
that defining a preferred tests should not restrict researchers from measuring other study specific 
endpoints of their choice 28. 
 
A recurring theme from the work around stroke outcomes was that a stroke trial should have some 
measure of functional recovery.  For many stroke trials, the modified Rankin Scale (mRS) was the 
primary outcome of choice 29.  Although widely used, mRS was not designed for use as trial outcome 
measure and there were certain problems in the psychometric properties of the scale, most notably 
around inter-observer variation in the grade assigned 30.  Having settled on a preferred outcome 
measure, the stroke research community developed methods to standardise mRS, including training 31, 
structured approaches to questioning 32, expert adjudication panels 33 and novel methods for analysis 
34, 35.  In respect of measuring cognitive outcomes in acute stroke trials, few did (e.g. 36) in spite of 
recommendations to do so 22, 23.  The substantial progress made around outcome assessment in clinical 
stroke research should serve as an exemplar for developing assessment strategies in other research 
fields.  Stroke assessment and VCI assessment are far from synonymous, but there is sufficient 
commonality in the diseases, the models and the research challenges for the VCI pre-clinical research 
to explore the potential application of recent methods used to raise standards in stroke research 
outcome assessment.   
 
Review of the literature  
To inform and give context to this work, we systematically reviewed the literature on outcome 
assessment in pre-clinical VCI research.  This work was taken from of a larger body of work with a more 
general pre-clinical, functional outcomes remit 37.   To complement this search of electronic literature 
databases, a search of the COMET and EQUATOR (Enhancing the Quality and Transparency Of health 
Research) databases found no existing work on core outcome sets for VCI, although preferred 
outcomes for clinical VCI research are in preparation.  In addition, we consulted the consensus working 
group with the Stroke Recovery Research Round Table (SRRRII) proceedings of a consensus working 
groups that is focusing on stroke-induced cognitive impairment 38.  
 
We assessed outcomes used in selected, published pre-clinical VCI studies over a decade’s worth of 
research (2005-2015) with dates chosen to reflect a period of growth in the VCI research space.  This 
was part of a larger project analysing preclinical stroke research that has been published and full details 
of methods and results are available in the parent publication 37.  From this work, we extracted data 
specific to VCI research.   
 
Across a decade of research, we found that VCI was less frequently studied than other aspects of 
stroke.  In those papers with a predominant VCI focus, there was substantial heterogeneity in outcome 
assessment with many tests used in two papers or more (Figure 1).  In addition to those listed, the 
following outcome assessments were described in only one paper: adhesive removal test, buried food 
retrieval (olfactory), circular hole board (dry maze), elevated plus maze, inclined plane test, limb 
placement test, nest construction test, porsolt swim test, social interaction in novel environment.  For 
the assessment that was used most often, the Morris Water Maze (MWM), we found marked 
inconsistency in how the test was performed and reported.  We had hoped to categorise the tests 
according to the cognitive domain being tested, but such data were infrequently reported.  These VCI 
findings mirror the results of a systematic analysis of studies using AD mouse models 39.  In transgenic 
mouse studies, there was heterogeneity in assessments employed, with the MWM was being the most 
commonly used test, yet marked variations in the conduct and analysis of the MWM testing were noted.  
There was a clear sex bias with 62% of studies using only male animals, 3% only female, 16% both 
sexes and 19% did not specify sex used 37.  Whilst we acknowledge a clear bias towards using males 
in preclinical research exists, we support and encourage the need to undertake more research using 
both sexes (males and females) given known sex differences exist. 
 
These data come with certain caveats, the search was restricted to priority journals with a 
cerebrovascular focus and so is not a comprehensive synthesis of VCI research.  We also recognise 
that VCI research, models and outcomes continue to evolve and some of the newer models of VCI, for 
example those that model amyloid angiopathy may be under-represented.  Thus, the focus and time 
frame may omit other VCI models (e.g. hypoperfusion, small vessel disease relevant) which are more 
representative of the milder end of the VCI spectrum and for which arguably there has been more 
extensive behavioural testing.  Accepting these limitations, our illustrative review offers some useful 
insights into outcome assessment in pre-clinical VCI work. 
 METHODS 
We collated opinions and practices around pre-clinical VCI assessment in UK academic centres.  With 
support from Alzheimer’s Research UK Scottish Network we held a one-day workshop, complemented 
by a questionnaire of usual practice.  The work had ethical approval from University of Glasgow, MVLS 
ethical committee (ref:200170103).  This work is the first in a planned series designed to raise standards 
in pre-clinical VCI research.  
 
Sampling frame: Our approach was purposive, using our own knowledge of VCI research and also 
consulted with Alzheimer’s Research UK and Dementia Platform’s UK Vascular Experimental Medicine 
Group to identify UK academic centres with an active VCI research laboratory.  From an initial approach, 
we asked respondents to name other researchers working in this space to allow for a snowball 
distribution.  Our focus was on neurocognitive and behavioural outcomes.  These are functional tests 
and do not include measures of pathology, neuroimaging or biomarkers.  To align with the clinical 
research literature we use the term ‘functional assessment’ to describe these tests.  
 
Questionnaire: We followed best practice in design, conduct and reporting of our questionnaire study 
40.  Academic centres that were involved in the workshop were first sent a short questionnaire by the 
study Principal Investigators (LW and TQ).  The bespoke questionnaire was designed and piloted in-
house before dissemination.  The questionnaire focussed on the functional outcome assessments used 
in pre-clinical VCI research and large vessel stroke models by the respondents.  Additional questions 
explored perceived heterogeneity in choice and application of functional outcome assessment 
measures.  The questionnaire was sent electronically with an explanatory cover letter (or by post on 
request) and up to two reminder messages were sent if no response was received.  No incentive was 
offered for completion.  It was stated that completion of the questionnaire implied consent to participate 
and a separate consent form was not used.  We aimed to include all relevant centres and so we did not 
perform sample size calculations.  Questionnaires were collated, results entered into a database and 
described in aggregate using simple descriptive statistics.  The questionnaire had space for free text 
comments, where these were completed verbatim comments were added to the results of the focus 
group discussion described below.  Recognising that more than one PI may work in a centre, we 
accepted more than one response from each Institute but asked that each team only submit one 
questionnaire.  The full questionnaire is available in supplementary materials (Figure S1).   
 
Workshop. We convened a one-day workshop on June 11th 2018 in the Institute of Cardiovascular and 
Medical Sciences, University of Glasgow, UK.  We used the same distribution list as the questionnaire.  
Primary invitation was to senior researchers within a centre, who also nominated early career 
researchers to participate where appropriate.  We used a focus group approach, with a moderator 
facilitating a semi-structured discussion with a small group, resulting in three groups with eight 
participants, one facilitator and one scribe.  The facilitator was one of three senior researchers with an 
interest in VCI (LW, TQ, CMcC), the scribe was an early career researcher who took notes during the 
discussions.   
 
The day began with an overview presentation that included the results of literature review (described 
above) and preliminary results from the questionnaire.  Two 1 hour discussions were then held, the first 
focussing on assessments used in the participants’ laboratory and the second focussing on the 
application of tests for VCI and other relevant models.   Topics covered during the discussions were 
guided by the group with the facilitator ensuring that the following themes were all addressed: choice 
of tests, rationale for choice, application of tests, core outcomes sets.  Each group offered feedback on 
their discussions with the others in the room and this conversation was also recorded by the scribe. 
 
Responses were recorded as free text and these data were shared with one of the research team (TQ) 
who collated the comments and categorised as common themes emerged.  This process was continued 
until all free text comments were categorised.  The resulting summary was electronically shared with all 
participants for comment or correction. The statements presented represent a final consensus on the 
topic.  We provide a narrative summary of the discussion, but as per our ethical approvals, we do not 
attribute responses to a particular participant.   
 RESULTS 
Questionnaire about choice of VCI outcome measures. 
We identified 12 centres in the UK, with an active VCI research portfolio.  For the questionnaire, we 
received replies from 23 researchers, with responses from 11/12 of the centres approached.  The 
majority, 18/23 (78%) of respondents, said they did not agree that research groups used the same tests 
in VCI research.  Similarly, the majority of responses, 21/23 (91%), said that the approaches used and 
scoring were not consistent. 
 
Respondents were asked to list all outcome measures that they used in VCI studies (Question 2, 
Supplementary Figure 1), which generated a list of 23 assessments, most of which were used by a 
single respondent (Table 1).  We used the test names as returned by the respondents and did not try 
to categorise these.  It could be argued that some responses with different names are essentially the 
same test.  Without knowing the detail of the test, we opted not to combine similar responses and 
instead present the responses as submitted.  Respondents interpreted the ‘functional’ assessment 
rubric in different ways and some of the tests reported would not classically be considered as 
neurobehavioral assessments.  The most commonly used test was Novel Object Recognition followed 
by the MWM.  The original intention was to group test by cognitive domain assessed.  This was not 
possible as some of the tests mapped across to various domains.  This difficulty in categorising VCI 
outcome assessments was a discussion point during our work-shop. 
 
Workshop discussion summaries 
The workshop included 30 participants, representing 12 different UK centres.  Participants were 14 
senior researchers (head of department, chair or principal investigator of a research group) and 16 early 
career researchers.  The comments generated were collated into six themes, each described below.  In 
addition, the group agreed on a set of consensus statements around current practice in pre-clinical VCI 
functional outcomes research and some priorities for future work in this area.  The themes, consensus 
statements and research priorities with shared with all contributors and other international experts.  
Revisions were collated centrally by the lead authors (LMW, TJQ), incorporated without attribution and 
revised materials shared with the group.  Process continued until no more changes were suggested.   
 
Theme 1: Issues with pre-clinical VCI models.   
The models most commonly used by the participants’ research groups were vessel occlusion models 
(permanent or transient); microembolic models; models using vascular risk factors and genetic 
vasculopathy models.  This is not an exhaustive list of models used by the participants and many other 
models were all discussed.  Each group raised issues around the suitability of functional assessment 
in some of the commonly used VCI models.  Many groups use murine models but there was debate 
around how well these models can capture the cognitive phenotypes similar to those seen in clinical 
VCI 41.  There may be little benefit in designing a test strategy to capture issues such as dysexecutive 
problems or language impairments, if the animal being tested does not have a basic level of ability in 
these domains even in health.  Some participants felt that aspects of executive function could be 
assessed in mice, using attentional control, working memory, rule learning and reversal-based 
assessment.  Some other laboratories are developing models in other larger species such as pig 42.  
The advantages to this approach were recognised, but these had to be weighed against the increased 
costs and ethical considerations of working with these animals.  Whilst larger animals including non-
human primates show some advantages for assessing cognitive impairments over rodents, there still 
remains the issue of not being able to assess language and speech.   
 
Another aspect of VCI models that was discussed was the role of lesion specific modelling versus 
models that create a more diffuse brain insult.  It was agreed that these different models require different 
approaches to functional assessment - domain specific testing may be relevant to models with precise 
lesioning (e.g. focal endothelin-1 injection), while a more global testing strategy may be useful in diffuse 
injury (e.g. global hypoperfusion through bilateral carotid stenosis).  Once again it was recognised that 
our limited understanding of the pathology of human VCI precluded any definitive statement on the 
optimal pre-clinical model that should be used.  The agreement was that whichever model is employed, 
the outcome assessments must be relevant to the intended brain lesion.  An alternative argument was 
made, rather than have the model dictate the outcome assessments, we could consider having the 
cognitive deficit of interest (i.e. the outcome) inform the choice of model. 
 
Theme 2: Reasons for choosing specific functional assessments.   
All groups discussed the assessments that they used in their laboratory and the reasons why one test 
was preferred over another.  A theme emerged that the rationale for using a particular assessment was 
often driven by practical considerations as well as science.  Groups described the time and training 
investment required to develop a functional assessment protocol that is reproducible and robust for a 
particular VCI model.  Once a protocol is established, this often meant that the included test was used 
in subsequent experiments and grant applications.  Groups were resistant to changing established 
practice unless clear benefit could be demonstrated.  It was recognised that the time and effort involved 
in becoming familiar with testing was a barrier to new groups beginning VCI research.  All these points 
supported the calls for greater sharing of resource and expertise. 
 
Some of the testing paradigms favoured in the participants’ centres had been modified from existing 
protocols used in non VCI based models particularly AD and stroke.  Ultimately it was recognised that 
choice of functional outcome assessment was not always driven by neuropsychological considerations.  
The example of the popular MWM was used, a test prevalent in VCI research but that does not capture 
frontal lobe anomalies involving executive dysfunction, attention, processing speed, reaction time and 
object recognition.  Vascular cognitive impairments span multiple domains and therefore no single 
measure is going to be appropriate to all VCI research.  Tests need to be validated for the domain of 
interest and if the function assessed spans more than one neuroanatomical hub, then more than one 
test may be required.   
 
Some groups discussed the potential for new technologies, with translational relevance, to improve 
outcome assessment 43.  The example most widely mentioned in resulting discussions was the use of 
touchscreen-based test batteries designed for rodent models but additionally relevant to the clinical 
setting.  Touchscreen based assessments have the potential to model human assessment tools and so 
could allow for greater pre-clinical and clinical harmonisation of assessment.  Although groups were 
aware of digital platforms that had been used for testing only one of the participants had expertise in 
using the technologies.  The group also had concerns over whether the cost, and often lengthy protocol, 
justified adopting these techniques in preference to more established assessment strategies.  There 
were also concerns over whether grant funding bodies would view these technologies as good value 
for money. 
 
Theme 2: Consensus point. 
• The functional outcomes measures that are best suited to the study of VCI will often differ from 
measures used in Alzheimer’s or other neurodegenerative pre-clinical research. 
 
Theme 3: Issues in the interpretation of functional assessments.   
There was a general recognition that all of the commonly used functional assessments had inherent 
limitations.  It was felt that this did not invalidate the use of the tests but interpretation of the results 
came with certain caveats.  The models used to induce VCI may not cause exclusive cognitive deficits.  
There is the potential for performance on functional tests to be confounded by other deficits for example 
a stroke motor deficit could bias timed cognitive tasks such as mazes 44.  The same problem is seen 
when testing cognition in clinical stroke 45 and only recently have test batteries been developed that 
take account of non-cognitive stroke deficits 46.  In most centres, researchers screen animals before 
testing to ensure they are fit for the assessment.  Assessment varied according to the model and the 
outcome being assessed and could include screening for motor, visual or other sensory impairments.  
It was felt that this could be formalised into a set of inclusion and exclusion criteria that must be met 
before testing and reported in results, a situation analogous to cognitive testing in clinical research 
studies. 
 
Another potential confounder, albeit more difficult to quantify, is seen in the emotional and stress 
response associated with the testing paradigm itself.  Many cognitive tests expose the animal to a novel 
situation or involve fear, reward, food deprivation etc.  These factors may bias test performance, 
although it was felt that this was less of an issue if a control group are exposed to the same tests.  
Habituation of animals to behavioural tasks needs also to be considered and standardised.  It was felt 
that experience and training could reduce but not entirely remove these confounding issues.   
 
All of these issues lead to an inherent variability in test performance and this in turn may necessitate 
large numbers to demonstrate between group differences.  Statistical power analysis should be required 
to define group sizes in VCI studies with functional outcomes to avoid underpowered studies. This was 
an argument to support standardisation of assessment and a move towards larger, multi-centre 
collaborative projects. 
 
The functional tests discussed were all designed to assess issues at the level of impairment.  In clinical 
research, outcomes may assess more complex constructs such as disability (activity) or handicap 
(participation) 47.  There was some discussion around whether higher level functional issues could be 
captured in pre-clinical models, for example through describing social behaviours, or daily activity such 
as nesting.  It was recognised that animal housing and bedding would need to be standardised if these 
behaviours were to inform any outcome measure. 
 
Some participants suggested that trying to make sense of functional assessments in pre-clinical models 
was, in fact, too ambitious.  The question was raised as to whether assessment of cognitive impairment, 
with attendant need for equipment and experienced staff, was even necessary.  Instead, some form of 
quantification of pathology, such as size of lesion (if appropriate to model) or change in a biomarker 
may be a sufficient outcome for preclinical research.  However, it was also noted that in clinical research, 
relying solely on a surrogate outcome has given misleading results and as a result for stroke research 
functional outcomes are now preferred.  
 Cognition is a complex construct with differing brain regions said to contribute to differing domains of 
cognitive performance, for example the most recent clinical definitions of neurocognitive disorder 
recognise attention, learning and memory, language, visuospatial, executive function and social 
cognition 48.  For some of the more popular functional tests, such as the MWM, it was noted that it can 
be difficult to categorise exactly, which cognitive domains are being assessed by the test of interest.  
The MWM is usually described in terms of learning and/or memory but other cognitive domains (e.g. 
visuospatial) are also involved in the execution of the task.  Mapping the cognitive domains being 
assessed to the available tests could assist in choice of test strategies for future research.  There was 
a recognition that working with behavioural neuroscientists and neuropsychologists can aid the design, 
conduct and interpretation of cognitive assessments, but that researchers with these skills were limited 
in preclinical academic centres.   
 
Theme 3: Consensus points 
• Choice of functional outcome in pre-clinical VCI research should take account of anticipated 
cognitive deficit, disease process being modelled and potential confounders.  
• Heterogeneity in choice, application and scoring of outcomes in pre-clinical VCI research limits 
the potential for comparison, collaboration and replication 
• A standardised set of screening assessments (e.g. motor, vision) could prevent confounding of 
cognitive outcomes.  These may be specific to the chosen cognitive assessments. 
 
Theme 4: Describing and reporting functional outcome assessments.   
Whether or not assessments are standardised to a consensus SOP, the testing strategy should be 
described in sufficient detail to allow for replication in another centre.  The groups noted that reporting 
of functional outcome assessment methods was variable and there is potential to improve practice.  The 
success of initiatives such as the Animal Research Reporting of In-vivo Experiments (ARRIVE) and 
other guidelines in raising standards around reporting of pre-clinical research was noted 49, 50.  However, 
the ARRIVE reporting checklist does not give specific guidance around reporting of outcome 
assessment methods, specifically how assessments were performed 51, 52.  
The complexity of functional assessment and the many potential factors that could influence test 
performance were considered.  As well as the potential variation in the actual test, factors specific to 
the animal (time since lesion, age, sex), factors specific to the environment (time of day, temperature, 
level of enrichment) and factors specific to the researcher (experience, contact time) could all modify 
test performance.  All these variables, and potentially many others, should be recorded and it was 
agreed that some guidance on the key factors that need to be described in protocols and papers would 
be useful.   
 
Not all animals complete a test as expected.  For example, one laboratory gave the example of mice 
that often do not perform MWM appropriately and consistently swim around the edge of the water rather 
than engage in the task.  These animals will not contribute any meaningful data to analyses and are 
excluded.  Such exclusions should be fully transparent and included in any report, perhaps using a 
CONSORT flow diagram style figure.   
 
In the past, a barrier to the comprehensive descriptions of different methods had been imposed by the 
word limits imposed in journals.  In present times, with greater availability and use of online 
supplementary materials this was felt to no longer be an issue.  Some delegates suggested that we 
could move towards greater use of video to document process and application of testing.  It was noted 
that many journals now mandate the use of reporting guidance (if available) before a study is considered 
for publication.   
 
Theme 4: Consensus point.  
• Standardisation and guidance on the reporting of outcomes in VCI research is needed. 
 
Theme 5: Sharing resources and expertise.   
A theme that dominated all the discussions was the need for greater collaboration and co-design among 
centres.  It was recognised that having different centres developing and improving methods and 
protocols for the same assessment but working in isolation was time and cost inefficient.  Many centres 
have developed their own materials such as training manuals, standardised operating procedures 
(SOPS) and ‘troubleshooting’ guides for outcome assessment but these are often only available for in-
house use.  Greater networking and collaboration between centres could facilitate information sharing.  
The Home Office licence approvals required for pre-clinical VCI work were recognised as another 
example of a potentially valuable resource that is required by all laboratories and that could be easily 
shared between centres.  In doing so this could lead to greater standardisation across the UK in the 
conduct of VCI studies, making the licensing procedure more efficient and streamlined, hopefully 
resulting in more rapid approval of new licences and amendments.  Informal communication between 
laboratories, on its own may not be sufficient to ensure visibility of the various resources available.  A 
free to access repository for training materials, SOPS etc was a suggestion that met with approval from 
all delegates.  Some members noted that in clinical stroke, online training in outcome assessment with 
certification had become standard 31.  Similar training could be developed for certain VCI outcomes.  As 
well as the potential time and cost savings of sharing resources, a single point of access repository 
could also allow the research community to map which outcomes had sufficient training materials and 
guidance which outcomes needed such materials to be developed.  
 
Theme 5: Consensus point. 
• The VCI research community needs a platform for sharing SOPS, training, equipment and 
archived tissue. 
 
Theme 6: Standardisation of outcomes.   
Groups were encouraged to discuss standardisation in choice and application of functional outcomes.  
Opinions on the utility of standardisation differed.  Many recognised the potential benefits but some 
group members also voiced reservations about an overly prescriptive approach.  Many participants 
mentioned that training in the application and interpretation of behavioural testing is not uniform across 
centres.  In particular, there will be differences between dedicated behavioural laboratories and more 
units with a more general portfolio.  
 
All groups discussed the potential of creating a core set of preferred functional outcome assessments.  
While this was broadly endorsed, there were some reservations.  Outcomes should not be mandated 
and researchers should still have the flexibility to use tests of their choosing.  In many circumstances, 
particularly in early phase experiments, the outcomes of interest need to be chosen to align with the 
hypothesis being tested.  The work of COMET emphasises that autonomy in choice of outcomes and 
use of a core outcomes set are not mutually exclusive 27.  The ideal scenario would involve a battery of 
different tests, including certain core assessments and also incorporating other tests specific to the 
experiment. 
 
There was general agreement amongst the delegates that a ‘one size fits all’ approach is not suited to 
exploratory pre-clinical research.  Functional outcomes of interest in pre-clinical VCI research span a 
variety of neurocognitive and behavioural domains.  Rather than a single preferred outcome, the group 
felt that a preferable approach was to create a menu of preferred tests, with tests suggested for all the 
various domains of interest. 
 
It was indicated that a move towards a standardised test battery would be premature as we do not yet 
have valid models that capture VCI and our understanding of clinical vascular dementia syndromes is 
still evolving.  The counter argument was that recommendations around tests could change in-line with 
scientific progress and it would be wrong to delay moves towards standardisation while important pre-
clinical VCI research was already in progress.  
 
At a practical level there was recognition that a consensus approach to outcome assessment that was 
described in a widely adopted standard operating procedure (SOP) would help with grant applications, 
scientific protocols and applications towards approvals required for animal-based research.  Many 
groups discussed the increasing interest in multi-centre, pre-clinical randomised controlled trials - 
pRCTs, with the Multicentre Preclinical Animal Research Team (Multi-PART) program of research cited 
as an exemplar of this approach 53.  However, it was recognised that this interest was not yet matched 
by a substantial increase in pRCT activity.  For true multi-centre work, an agreed and standardised 
approach to outcome testing would be essential, along with full support of grant awarding bodies to 
fund such work.  At the moment pRCT science is still at an early phase and it may be difficult to mandate 
standardisation, when the approach is still being refined.   
 
Theme 6: Consensus points.  
• A single mandated outcome assessment would not be suitable for a complex construct such 
as VCI. 
• A menu of preferred assessments for each cognitive domain could improve standardisation. 
 
DISCUSSION 
Using a multi-modal approach we attempted to capture current practice and perceptions around 
functional testing in pre-clinical VCI research.  In this report we analyse and summarise the results of 
our literature search, questionnaire survey and focus group.  Our review of selected, published VCI 
research suggested substantial heterogeneity in the choice and application of cognitive tests.  Also, that 
the majority of VCI studies use male animals and fail to address the issue of sex bias in pre-clinical 
research highlighting the need to improve this important area.  Researchers should be encouraged to 
investigate both males and females in VCI studies.  Our questionnaires showed that inconsistency in 
assessment is a recognised as an issue by the research community.  To give these results context and 
to explore the issues with greater granularity we ran focus group discussions.  Although there were 
differing opinions around certain aspects of testing, there was substantial common ground and we were 
able to agree on consensus statements and priorities for future research (Textbox 1 and 2). 
 To ensure that our process was robust, we engaged with various stakeholder groups to ensure that we 
achieved broad representation from the UK research community.  All of the centres that we approached 
participated in either the questionnaire or focus groups.  We ensured we had representation both from 
senior research leaders and from` those earlier in their research career who may have more direct, day-
to-day experience with performing assessments.  We sensed checked our results with international 
experts, who noted no issues with generalisability of the main recommendations, and used an iterative 
approach to refining our consensus statements and research priorities. 
 
There are also limitations to our approach.  It is possible that our sampling frame missed UK research 
groups with an active VCI interest.  We plan future, collaborative methodological work that builds on 
this project and any centres that wish to contribute in the future can contact us.  For this phase of the 
work, our focus was the UK.  The VCI research space is international and in particular we recognise 
the work in this area undertaken by National Institute of Health and National Institute of Neurological 
Disorders and Stroke raising similar issues within the AD and Related Dementias Summit 2019 52.  Our 
international groups are also working towards consensus in VCI, such as Stroke Recovery and 
Rehabilitation Roundtable who are developing guidelines for improved translation of cognitive 
assessments after stroke that span both preclinical and clinical assessments 54.  In the present work, 
we limited the geographical scope of this first project as we recognised that approvals and regulation 
of pre-clinical research can vary internationally.  However, in many respects, the UK sample may not 
necessarily differ from international experience as we use the same variety of methods as are employed 
globally.  Before recommendations can be made around VCI assessment, we would wish to repeat the 
exercise with a broader, international group.  The synthesis of the focus group discussion was as 
objective as possible but there is always an element of interpretation.  To ensure that what we report is 
an accurate representation we shared all the data with participants, incorporating feedback and 
suggested changes until no more alterations were needed.  
 
Our discussion and recommendations were developed exclusively from the results of our literature 
review, questionnaire and consensus meeting and, accordingly, focused on outcome measures rather 
than choice of model.  From these sources the predominant models and approaches were rodent, for 
example in our literature review only 2% of relevant VCI studies used non-rodent models.  This finding 
is in keeping with other recent reviews of VCI models, where the non-rodent models were all larger 
species (eg ruminants) 42.  The potential differences between mouse and rat VCI models was not a 
major feature of our review or others55 suggesting that these differences are perceived as less important 
than other factors in the VCI community.  General messages are applicable, for example ensuring 
validity of assessments across animals and the trade-off of cost/access versus similarity to the human 
clinical condition.  The use of drosophila and zebrafish is gaining increasing traction in Alzheimer’s 
disease dementia where exciting results are being produced with these species 56.  Our results would 
suggest that these models have less visibility in the VCI field.  Hence, while this paper focuses on 
outcome measures we appreciate the importance of having a valid model and plan further work in this 
area. 
 
The consensus conclusions and research priorities that resulted from this project are presented in the 
text boxes.  We believe these will prove useful to researchers but also to funders and journal editors.  
We were encouraged by the willingness of the pre-clinical VCI research community to work together on 
this project and believe it could serve as an exemplar for future methodological work.  Other areas that 
could benefit from similar consensus and guidance include choice of VCI models and methods of 
analysis.  In other areas of stroke and dementia research, collaboration, consensus and pooling of 
resources has driven forward the research agenda 57.  Hopefully our experience in bringing together 
UK pre-clinical VCI researchers is the beginning of many future collaborative activities. 
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Figure 1: Outcome assessments used in across a decade of published VCI pre-clinical research.  
Outcomes described across VCI research published (n=37 articles) in selected journals 2005-2015 in 
more than 2 articles. 
  
Table 1: Reported outcome measures used in UK VCI pre-clinical research centres  
Test No Test No Test No 
Novel object recognition 5 Classical conditioning 1 Pole test 1 
Morris water maze 4 Forced swimming task 1 Rotarod 1 
Radial arm maze 3 Locomotor activity 1 Spatial recognition 1 
Barnes maze 2 Modified Bederson 1 Sticky label 1 
Neurovascular coupling 2 Nest building 1 T maze 1 
Operant conditioning 2 Neuronal activity 1 Tail suspension table 1 
Y maze 2 Open field 1 Touchscreen tests 1 
Asymmetry 1 Paw placement 1 Visual acuity 1 
 
  
Textbox 1 UK consensus on pre-clinical VCI functional outcomes   
• Choice of functional outcome should take account of anticipated cognitive deficit, disease 
process of interest and potential confounders.  
• Heterogeneity in choice, application and scoring of outcomes limits potential for comparison, 
collaboration and replication.  
• A standardised set of screening assessments (e.g. motor, vision) could prevent confounding of 
cognitive outcomes. These may be specific to the chosen cognitive assessments. 
• The VCI research community needs a platform for sharing SOPS, training, equipment and 
archived tissue. 
• The functional outcome measures that are best suited to the study of VCI will often differ from 
measures used in Alzheimer’s or other neurodegenerative pre-clinical research. 
• A single mandated outcome assessment is unlikely be suitable for a complex construct such 
as VCI  
• A menu of preferred assessments for each cognitive domain will improve standardisation 
• Standardisation and guidance on the reporting of outcomes in VCI research is needed. 
 
 
  
Textbox 2 Future research directions for pre-clinical VCI functional outcomes  
• Mapping available outcome measures to (clinical) cognitive domains. 
• Work with funders and journals to developing reporting guidelines for outcomes. 
• Need to explore role of new technologies. 
• Explore developing multicentre approaches to VCI research.  
• Broaden this work to gain an international consensus. 
 
 
